RxDoctor Payments Data

Seyed Sajjadi, PhD

Behavioral Neurology & Neuropsychiatry · Orange, CANPI 1750733325

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,550 of the $9,560 with a category attached, or 89.4%. Eisai Inc. accounts for 76.8% of it on its own, with 2 other manufacturers making up the rest.

$9,560in general payments, 2019–2025

Across 13 payments — averaging $735.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$7K
  • Genentech, Inc.$2K
  • Life Molecular Imaging Ltd$33
$113,300in research payments, 2019–2025

Across 30 payments — averaging $3776.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$113K

What the payments were for

  • Consulting fees$8,55089%
  • Travel & lodging$7568%
  • Food & beverage$1401%
  • Education$1141%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.8$7,343
Genentech, Inc.4$2,184
Life Molecular Imaging Ltd1$33

How this compares

Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$47,034
Medicare patients
243
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole25$50,418
Rivastigmine51$13,654
Memantine Hcl218$9,194
Memantine Hcl ErMemantine Hcl29$4,401
Donepezil Hcl245$2,670
Quetiapine Fumarate70$809
Citalopram HbrCitalopram Hydrobromide78$713
Levetiracetam19$611
Mirtazapine30$452
Escitalopram Oxalate27$429
Carbidopa-LevodopaCarbidopa/Levodopa13$298
Trazodone Hcl23$246
Sertraline Hcl15$95
Clonazepam19$37

Paid to pharmacies, not to this prescriber.

Other behavioral neurology & neuropsychiatry in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →